Tatyana Poltyrev

Effect of prenatal stress on plasma corticosterone and catecholamines in response to footshock in rats

The effect of prenatal stress was investigated on the sympathoadrenal response to novelty and footshock by measuring the time course of the changes in circulating corticosterone (COR) catecholamines and their metabolites. Pregnant rats were subjected to noise and light stress, three times weekly on an unpredictable basis throughout gestation. When the male offspring of stressed rats (PS) and those of unstressed mothers (C) were 4.5-5 months of age, they were prepared with indwelling catheters in the tail artery 24 h before the experiment. Resting levels of plasma COR, noradrenaline (NA), adrenaline (AD), dihydroxyphenylglycol (DHPG), dihydroxyphenylacetic acid (DOPAC), and dihydroxyphenylalanine (DOPA) were measured. Further blood samples were taken within 3 min of their transfer to the shock box, 1-2, 5, 15, and 45 min after footshock. Plasma COR was significantly higher in PS than in C rats at rest, but those of adrenaline, NA, and their metabolites did not differ in the two groups. Transfer of the rats to the shock box increased plasma COR, NA, adrenaline, and dihydroxyphenylglycol in both groups, and dihydroxyphenylalanine and dihydroxyphenylacetic acid only in PS rats. All the catechols increased further 2-3 min after footshock, except dihydroxyphenylalanine in PS rats. Plasma NA and dihydroxyphenylglycol levels were significantly higher in PS than in C rats immediately after footshock, indicating a greater activation of the sympathetic nervous system in PS rats. The findings demonstrate for the first time that prenatal stress can induce long term changes in the sensitivity of the sympathoadrenal system to stress.

Prenatal Stress Depresses Immune Function in Rats

The aim of the present study was to determine the effect of prenatal stress on immune function in rats. Pregnant rats were stressed by noise and light, three times weekly throughout pregnancy. Experiments were performed on male and female offspring aged 2 months. Cellular immune responses of splenic lymphocytes to B-cell (pokeweed mitogen (PWM) and T-cell (phytohemagglutinin (PHA)) mitogens were measured by [3H]thymidine uptake, and natural killer (NK) cell cytotoxicity in blood and splenic lymphocytes was measured against the murine T-cell lymphoma, YAC-1, by a 4-h [51Cr] release assay. Prenatal stress suppressed immune function as shown by a) decreased NK cytotoxicity in splenic and blood lymphocytes, indicating that the effect was not confined to a particular immune compartment, and b) decreased rate of proliferation of splenic lymphocytes to PWM and a smaller depressant effect on their response to PHA. The suppression of B-cell proliferation was more marked in the female and that of NK cell cytoxicity, in the male. Prenatal stress did not alter the distribution of subsets of lymphocytes, in either the spleen or blood, indicating that the reduction in proliferative and cytotoxic activity resulted from functional modifications of effector mechanisms in the cells rather from alterations in their migration between immune compartments. The mechanisms underlying this effect of prenatal stress are not clear but could result from an action of maternal stress hormones on the developing fetal neuroendocrine system.

Role of experimental conditions in determining differences in exploratory behavior of prenatally stressed rats

The effect of prenatal stress was determined on exploration in situations that induce different levels of fear. Dams (12) were stressed by noise and light thrice weekly on an unpredictable basis throughout pregnancy, and 12 controls were left undisturbed. The time spent by different groups of their adult offspring of both sexes in exploration was assessed during 4 min in a plus maze; large, well-lit open field (1), and open field (2) after prior exposure to a small, dark holebox. Prenatal stress resulted in a significant reduction in the number of arm entries in the plus maze and amount of time spent in the open arms. Locomotion and rearing were also reduced in Open Field 1 and 2, but these activities and hole poking were unchanged in the holebox. It is concluded that prenatal stress renders the animal more fearful to a novel, intimidating environment, which may be expressed as a suppression of exploratory activity.

cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs.

Summary.  Background. Chronic antidepressant treatment causes alterations in several hippocampal genes, which participate in neuronal plasticity. However the full picture of their mechanism of action is not known. The advent of genomics enables to identify a broader mechanism of action and identify novel targets for antidepressant development. Methods. The present study examined the cDNA microarray gene expression profile in the hippocampus induced by chronic antidepressant treatment, in rats exposed to the forced swim test. Animals were treated for 2 weeks with moclobemide, clorgyline and amitriptyline. Results. The three antidepressants significantly reduced immobility in the forced swim test and initiated significant homologous changes in gene expressions. These include up regulation of cAMP response element binding protein and down regulation of corticotrophin releasing hormone. Other gene changes noted were those related to neuropeptides, neurogenesis and synaptogenesis, including synaptophysin and neogenin. Some 89 genes were changed by at least 2 drugs, out of which 53 were changed oppositely by forced swim test. Confirmation of gene changes, have come from real time RT-PCR. Conclusions. A significant number and homology in gene expression were observed with the three antidepressants. Many of the genes were associated with neurogenesis and synaptogenesis, including synaptophysin and neogenin.

A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

Degeneration of cholinergic cortical neurons is one of the main reasons for the cognitive deficit in dementia of the Alzheimer type (AD) and in dementia with Lewy bodies (DLB). Many subjects with AD and DLB have extrapyramidal dysfunction and depression resulting from degeneration of dopaminergic, noradrenergic and serotoninergic neurons. We prepared a novel drug, TV-3326 (N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), with both cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity, as potential treatment of AD and DLB. TV-3326 inhibits brain acetyl and butyrylcholinesterase (BuChE) in rats after oral doses of 10-100 mg/kg. After chronic but not acute treatment, it inhibits MAO-A and -B in the brain by more than 70% but has almost no effect on these enzymes in the small intestine in rats and rabbits. The brain selectivity results in minimal potentiation of the pressor response to oral tyramine. TV-3326 acts like other antidepressants in the forced swim test in rats, indicating a potential for antidepressant activity. Chronic treatment of mice with TV-3326 (26 mg/kg) prevents the destruction of nigrostriatal neurons by the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). In addition to ChE and MAO inhibition, the propargylamine moiety of TV-3326 confers neuroprotective activity against cytotoxicity induced by ischemia and peroxynitrite in cultured neuronal cells that results from prevention of the fall in mitochondrial membrane potential and antiapoptotic activity. These unique multiple actions of TV-3326 make it a potentially useful drug for the treatment of dementia with Parkinsonian-like symptoms and depression.

Ladostigil prevents age-related glial activation and spatial memory deficits in rats.

Oxidative stress and glial activation occur in the aging brain. Ladostigil is a new monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibitor designed for the treatment of Alzheimers disease. It has neuroprotective and antioxidant activities in cellular models at much lower concentrations than those inhibiting MAO or AChE. When ladostigil (1mg/kg/day) was given for 6 months to 16-month-old rats it prevented the age-related increase in activated astrocytes and microglia in several hippocampal and white matter regions and increased proNGF immunoreactivity in the hippocampus towards the levels in young rats. Ladostigil also prevented the age-related reduction in cortical AChE activity and the increase in butyrylcholinesterase activity in the hippocampus, in association with the reduction in gliosis. The immunological and enzymatic changes in aged rats were associated with improved spatial memory. Ladostigil treatment had no effect on memory, glial or proNGF immunoreactivity in young rats. Early treatment with ladostigil could slow disease progression in conditions like Alzheimers disease in which oxidative stress and inflammatory processes are present.

Effect of Prenatal Stress on Opioid Component of Exploration in Different Experimental Situations

Prenatal stress interferes with the expression of opioid systems in rats. The present study determined the effect of prenatal stress on the opioid-influenced component of exploratory behavior, defined as the difference between the behavior of vehicle-treated and naloxone-treated rats, in three novel situations previously shown to cause different degrees of arousal. Pregnant rats were stressed three times weekly on a random basis by noise and flashing lights. Experiments were performed on 60-70-day-old offspring (male and female) of control and stressed dams. Fifteen minutes after injection of vehicle or naloxone (1 mg/kg), the proportion of time spent in eight different behavioral parameters, including locomotion, rearing, sniffing, hole poking, pivoting, and grooming, was assessed during 4 min of exposure to an open field, either with or without prior exposure to a hole box. The magnitude of the depressant effect of naloxone on exploration depended on the nature of the environment, previous experience of the animal in another situation, and the parameter of exploration assessed. The opioid-influenced component of locomotion and rearing was significantly reduced by prenatal stress, particularly in female rats. Further studies using a cross-fostering design are needed to assess the relative contributions of pre- and postnatal factors to the reduction of opioid activity in prenatally stressed rats. More specific opioid antagonists could be used to determine the nature of the opioid receptors involved.

TV3326, A Novel Cholinesterase and Mao Inhibitor

Alzheimer’s (AD) and Parkinson’s disease (PD) are progressive neurodegenerative conditions in which a decrease is believed to occur in the activities of mitochondrial enzyme systems (Ghosh et al., 1998; Swerdlow et al., 1998). The cognitive deficits in AD are associated with a loss of cholinergic neurones arising in the basal forebrain (Whitehouse et al., 1981), but also appear in some subjects with PD (Homann et al., 1998). Degeneration of nigrostriatal dopamine neurones, characteristic of PD, is seen to a lesser extent in AD. In both conditions, there are significant reductions in serotoninergic and noradrenergic projections from the dorsal raphe and locus ceruleus nuclei, respectively (Palmer, 1988). These reductions may be responsible for the relatively high incidence of depression that is found as co-morbidity in AD and PD (Newman, 1999; Murray, 1996). In order to delay the rate of progression of the neurodegeneration and ameliorate the cognitive deficits and depressive symptoms we designed a new drug, TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, a selective monoamine oxidase (MAO)-B methyl carbamate], derived from rasagiline, a selective monoamine oxidase (MAO)-B inhibitor (Youdim et al. 2001). The N-propargylamine moiety has been shown to confer neuroprotectiv activity on this and related molecules (Weinstock et al., 2001, Youdim and Weinstock, 2001; Youdim et al., 2001), and reduces the apoptosis and fall in mitochondrial action potential induced by oxidative stress in human neuroblastoma cells (Maruyama et al. 2000). Moreover, rasagiline was recently shown to delay the progression of motor impairment in PD (Parkinson Study Section, 2000; Rabey et al., 2000).